Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) has a beta of 1.61. The stock’s Relative Strength Index (RSI) is 56.53, with weekly volatility at 4.52% and ATR at 0.95. The SNDX stock’s 52-week price range has touched low of $13.02 and a $27.85 high. Its shares traded lower over the last trading session, losing -2.71% on 06/10/21. The shares fell to a low of $18.78 before closing at $19.00. Intraday shares traded counted 0.47 million, which was 46.85% higher than its 30-day average trading volume of 879.07K. SNDX’s previous close was $19.53 while the outstanding shares total 51.50M.
Investors have identified the Biotechnology company Syndax Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $919.79 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Syndax Pharmaceuticals Inc. (SNDX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For SNDX, the company has in raw cash 64.39 million on their books with 4.63 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 278.95 million total, with 24.57 million as their total liabilities.
Potential earnings growth for Syndax Pharmaceuticals Inc. (SNDX)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/10/2021 quarter of the year, Syndax Pharmaceuticals Inc. recorded a total of 0.38 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.0% coming in sequential stages and their sales for the 08/10/2021 quarter reducing by -0.26%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 0.38 million trying to sell their products during the last quarter, with the result yielding a gross income of 27.54 million. This allows shareholders to hold on to 51.50M with the recently reported earning now reading -0.54 cents per share. This is a figure that compared to analyst’s prediction for their 08/10/2021 (-0.54 cents a share).
Having a look at the company’s valuation, the company is expected to record -2.34 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SNDX sounds very interesting.
Is the stock of SNDX attractive?
In related news, SVP, Chief Medical Officer, Meyers Michael L. bought 500 shares of the company’s stock in a transaction that recorded on Apr 26. The purchase was performed at an average price of 15.46, for a total value of 7,730. As the purchase deal closes, the Director, Podlesak Dennis now bought 13,967 shares of the company’s stock, valued at 197,077. Also, Director, Egros Fabrice sold 10,241 shares of the company’s stock in a deal that was recorded on Mar 01. The shares were cost at an average price of 24.31 per share, with a total market value of 248,981. Following this completion of disposal, the Chief Executive Officer, Morrison Briggs now holds 35,156 shares of the company’s stock, valued at 722,403. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.40%.
5 out of 7 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Syndax Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the SNDX stock. The 12-month mean consensus price target for the company’s shares has been set at $27.83.